Sesen Bio Inc

Sesen Bio — Q1 2019 Earnings Presentation

45 slides from Sesen Bio's earnings presentation, May 13, 2019

  1. Slide 1: 1Q 2019 Business Update

    1Q 2019 Business Update May 13, 2019 NASDAQ SESN

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and our ability to successfully develop our product candidates and complete our planned uncertainties. All statements, other than statements of historical facts, contained in this clinical

  3. Slide 3: Our path forward starts with the patient journey

    BLOOD IN URINE See PCP; therapeutic OUR PATH FORWARD STARTS trial of antibiotics prescribed WITH THE PATIENT JOURNEY Still see blood in urine See blood in urine; Patient surveys have shown that the experience of those Confusion and concern on problem try different antibiotic with bladder cancer is o

  4. Slide 4: Agenda

    MAY 13, 2019 AGENDA 1. Updated Phase III data further demonstrate a compelling benefit-risk profile* 2. Strong regulatory and commercial probability of success 3. Simple, reliable and inexpensive manufacturing process *Updated Phase III data are as of the March 1, 2019 data cut 4

  5. Slide 5: 2019 Outlook

    2019 Outlook Cash runway into 2020, with no outstanding debt March 31, 2019 March 31, 2018 Cash and Cash $42.4M $19.7M Equivalents Important upcoming milestones with FDA* Type of FDA Meeting Confirmed Meeting Date Type C CMC Meeting May 20, 2019 Type B Pre-BLA Meeting June 6, 2019 *Note: Timing and

  6. Slide 6: Long-term partnership with the agency shapes our program in line with FDA guidance

    Our long-term partnership with the agency has allowed us to shape our nonclinical and clinical program in alignment with FDA guidance 2018 FDA Guidance Vicinium Clinical Program • Conduct nonclinical studies to assess toxicity in animal models � • Conduct nonclinical studies to demonstrate anti-tumo

  7. Slide 7: Vicinium demonstrates a strong benefit-risk profile in Phase III

    Vicinium demonstrates a strong benefit-risk profile in our Phase III Trial Efficacy Surrogate Time to Health Endpoints Cystectomy Outcomes Benefit : Risk Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkp

  8. Slide 8: Complete Response Rate: Phase II and Phase III consistent

    PII & PIII Complete Response Rate: Our Phase II and Phase III clinical trials are highly CIS Patients consistent for Complete Response Rate Complete Response Rate (CRR) in Carcinoma in situ Patients 50% Legend: Phase II (n=45) * 40% Phase III (n=91/93) 40% 39% 95% CI 30% 27% 28% 20% 21% 18% 16% 15%

  9. Slide 9: Complete and Partial Response in Phase II

    Complete and Partial Response: In our Phase II clinical trial, 83% of PII patients had a complete or partial response CIS Patients 3-Month Response ~40% of patients had a complete response Start of Treatment with ~43% of patients had a partial response Vicinium ~17% of patients have no response *Not

  10. Slide 10: Duration of Response

    Duration of Response: 54% of CIS patients who were complete responders at 3 PIII months remained disease-free for a total of 12 months after starting treatment CIS Patients Median Duration of Response is 288 days (95% CI, Each time point a CR is confirmed, the probability of 155-NE* days) (9.5 month

  11. Slide 11: Time to Disease Recurrence

    Time to Disease Recurrence: For high-risk papillary patients who were PIII Papillary treated with Vicinium, 50% are disease-free at 1 year Patients Median time to recurrence is 402 days (95% CI, 170-NE* days) 100 (13.2 months) Legend: 80 KM Estimate X Censored free - 95% CI 60 50% 40 36% % % of Pati

  12. Slide 12: Time to Cystectomy

    Time to Cystectomy: The average patient remains cystectomy-free for PIII 854 days (~28 months) after treatment with Vicinium All Cohorts Responders are ~15 times more likely than non-responders to remain cystectomy-free at 2.5 years 100 80 free - 60 Median 40 Legend: KM Estimate 20 X Censored % % Pa

  13. Slide 13: Progression-Free Survival

    Progression-Free Survival: >85% of patients treated with Vicinium are PIII estimated to remain progression-free at 2 years All Cohorts 100 87.6% 80 free - 60 Median 40 Legend: % % Patientsof Progression 20 KM Estimate X Censored 95% CI 0 0 3 6 9 12 15 18 21 24 Time on treatment (months) KM Evaluable

  14. Slide 14: Event-Free Survival and Overall Survival

    Event-Free Survival and Overall Survival: Early data is encouraging for PIII Event-free and Overall survival for patients treated with Vicinium All Cohorts Event-Free Survival Time Point Evaluable Patients Event-free Survival (95% CI) 6-months 128 41% (32%-49%) 12-months 119 30% (22%-38%) 18-months

  15. Slide 15: Safety and Tolerability: Phase III

    Safety and Tolerability: In our Phase III trial, AEs were generally low grade PIII and resulted in a low rate of discontinuation All Cohorts Treatment-Related AEs All AEs (% patients) (% patients) Any AE Urinary tract infection Dysuria Hematuria Pollakiuria (frequency of urination) Micturition urgen

  16. Slide 16: Safety and Tolerability: Phase II and Phase III consistent

    Safety and Tolerability: Our Phase II and Phase III clinical trials are highly PII & PIII All Cohorts consistent for safety and tolerability Increased dosing in the Phase III trial does not lead to an increase in incidence or severity of AEs Phase II Phase III Category (n=46) (n=133) Treatment-relat

  17. Slide 17: Totality of Phase III data suggest strong probability of success

    PIII Totality of Phase III data suggest a strong regulatory and commercial All Cohorts probability of success Endpoint How Endpoint is Measured Preliminary Results Complete Response Rate (CRR) • 39% CRR at 3 months Defined as the proportion of patients who show no evidence of high-risk Primary Endpo

  18. Slide 18: Agenda

    MAY 13, 2019 AGENDA 1. Updated Phase III data further demonstrate a compelling benefit-risk profile 2. Strong regulatory and commercial probability of success 3. Simple, reliable and inexpensive manufacturing process 18

  19. Slide 19: Virtuous Cycle: physicians, patients and payers as advocates

    Virtuous Cycle: High possibility that all three key segments are advocates & take action Physicians (Ancillary HCPs) Patients Payers (Caregivers/ Encourage use of Vicinium before RC (Private/ families) public) Advocate for product reimbursement Sources: Sesen Bio internal market research: Patient Jo

  20. Slide 20: Addressable Market (US)

    Addressable Market (US) Annual Volume ~80K1 Patients diagnosed with bladder cancer ~75% - 85% of bladder cancer diagnoses are NMIBC2 Patients diagnosed with NMIBC ~40% - 50% of NMIBCs are high-risk3 Patients with high-risk NMIBC: Papillary: ~80%2 CIS: ~20%2 ~50% - 90% of BCG treatments fail or disea

  21. Slide 21: Pricing and Reimbursement (US)

    Pricing and Reimbursement (US) Price Reference Payer Management Responses (Annual Cost)1 to Pricing2 100% $200K CI 3 Price Range of Checkpoint CI 2 Inhibitors (CIs) for CI 1 Urothelial Carcinoma $150K 50% Proportion of Payers $100K 0% $30 K $60 K $90 K $150 K $50K Unrestricted Coverage PA to Label K

  22. Slide 22: OUS opportunity for Vicinium is larger than the US

    We estimate the OUS opportunity for Vicinium is larger than the US Geography Incidence Relative to U.S.1 Price Relative to U.S.2 EU5 1.2 – 1.4 0.50 – 0.71 Japan 0.4 – 0.6 0.60 – 0.70 Rest of Europe 1.0 – 1.2 0.60 – 1.10 (Not including EU5) North America 0.1 – 0.3 0.55 – 0.70 (Not including U.S.) Sou

  23. Slide 23: Agenda

    MAY 13, 2019 AGENDA 1. Updated Phase III data further demonstrate a compelling benefit-risk profile 2. Strong regulatory and commercial probability of success 3. Simple, reliable and inexpensive manufacturing process 23

  24. Slide 24: Manufacturing of Vicinium is simple, reliable and inexpensive

    Manufacturing of Vicinium is simple, reliable and inexpensive 2000 L Production Centrifugation Bioreactor (bulk solids removal) Filtration (MF for fine solids removal and UF/DF for buffer exchange) Cell Bank Shake flask 5 Column Purification DP Fill Finish (7 mL @ 5mg/mL) 1: Q-Sepharose FF 2: Ni2+ I

  25. Slide 25: Vicinium Comparability Strategy

    Vicinium Comparability Strategy Guidance “If a manufacturer can provide assurance of comparability through analytical studies alone, nonclinical or clinical studies with the post-change product are not warranted.”1 Sesen’s analytical comparability plan is comprised of 4 key elements: 1. Analytical R

  26. Slide 26: Sesen Bio Highlights

    SESEN BIO HIGHLIGHTS 1. Updated Phase III data further demonstrate a compelling benefit-risk profile 2. Strong regulatory and commercial probability of success 3. Simple, reliable and inexpensive manufacturing process 26

  27. Slide 27: Appendix

    Appendix sesen ca

  28. Slide 28: Phase III Trial: Patient Demographics

    Phase III Trial: Patient Demographics COHORT 1 COHORT 2 COHORT 3 CHARACTERISTICS CIS that recurred within 6 CIS that recurred >6 Papillary tumors (without months of adequate BCG months but ≤11 months of CIS) that recurred within adequate BCG 6 months of adequate (Refractory) (Relapsing) BCG Total pa

  29. Slide 29: Phase III Data Tables by Cohort for Carcinoma in situ

    Phase III Trial: Data Tables by Cohort for Carcinoma in situ Cohort 1 (n=86) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=86 37% (27%-48%) 6-months n=86 26% (17%-36%) 9-months n=85 19% (11%-29%) 12-months n=84 15% (9%-25%) Cohort 2

  30. Slide 30: Additional Vicinium Clinical Data

    Additional Vicinium Clinical Data Preliminary Phase III vs. Phase II Complete Response Rate Time Point Phase III Pooled CRR (95% Confidence Interval) Phase II Pooled CRR (95% Confidence Interval) 3-months 39% (29%- 49%) 40% (26%-56%) 6-months 28% (19%-38%) 27% (15%-42%) 9-months 21% (13%-30%) 18% (8

  31. Slide 31: Complete Response Rate vs. Valstar

    PIII Complete Response Rate: We believe our 95% confidence interval rules CIS Patients out the CRR for Valstar and a clinically unmeaningful CRR Complete Response Rate 40% Legend: 38% 35% 95% CI 30% 28% Vicinium Duration of response for patients with 25% 24% CR at 6 months: Valstar: 13.5 months 1 20

  32. Slide 32: Duration of Response: probability of maintaining complete response

    PIII Duration of Response: For patients treated with Vicinium, at each time point a CIS Patients CR is confirmed, the probability of maintaining a CR increases Probability of Maintaining Complete Response for at Least Probability of Maintaining Complete Response for at Least One Year After Start of

  33. Slide 33: Duration of Response: patients treated with less BCG

    Duration of Response: Vicinium is generally more efficacious in CIS patients PIII treated with less BCG CIS Patients Median Duration of Response is longer in patients receiving adequate BCG than those receiving additional BCG cycles: 366 days (95% CI, 273-NE* days) (12.0 months) vs. 167 days (95% CI

  34. Slide 34: No age-related increase in adverse events

    Safety and Tolerability: No age-related increase in adverse events in our PIII Phase III trial All Cohorts Adverse Events 6 Treatment-related Adverse Events 5 5.0 4.7 4.2 4 3 2 1.8 Mean AEs patientper Mean 1.6 1 0.9 0 54-69 70-79 80+ (n=40) (n=57) (n=36) Age (years) Note: Data reflected consist of p

  35. Slide 35: Vicinium is a small, single protein strand targeting cancer cells

    Vicinium is a small, single protein strand that selectively targets cancer cells Antibody Exotoxin A Linker Fragment Payload • Antibody fragment (scFv) targeting EpCAM linked to a cytotoxic payload (Pseudomonas exotoxin A) to form a single protein • EpCAM over-expressed in cancer cells • Highly sele

  36. Slide 36: Vicinium: Dual Mechanism of Action

    Vicinium: Dual Mechanism of Action Mechanism 1: Exotoxin A Payload Kills cell directly Non-cleavable Ligand-checkpoint peptide Linker Vicinium interaction deactivates Antibody Fragment anti-tumor response Checkpoint Vicinium selectively Vicinium does not induce expression T cells recognize targets E

  37. Slide 37: Carcinoma in situ: the most difficult form of NMIBC to treat

    Carcinoma in situ: the most difficult form of NMIBC to treat Carcinoma in situ vs. Normal Bladder Lining: Clinical Trial Implications: • Field change disease often involving the entire bladder lining that is very difficult to treat • Failed on two or more courses of BCG, which is the gold standard f

  38. Slide 38: Bladder cancer is highly prevalent with tremendous unmet need

    Bladder cancer is highly prevalent with tremendous unmet medical need ~550,000 New Cases Each Year Globally1 • $4B+ in annual treatment costs for bladder cancer in the US alone2 Europe 3 ~195K • 75-85% diagnosed as NMIBC North America ~95K • Limited treatment options for high-risk NMIBC - Only three

  39. Slide 39: Only ~1,500 urologists account for the bulk of NMIBC treatment

    Only ~1,500 Urologists account for the bulk of NMIBC treatment and are concentrated in group practices allowing for a very efficient commercial model ~60% of Urology practices have ≥5 Urologists1 BCG Prescribers2 100% 90% 80% 70% 60% ~1,500 Urologists treat 75% of patients 50% % of Patients % 40% 30

  40. Slide 40: Global BCG shortage expected to last through 2019

    Latest global BCG shortage expected to last at least through remainder of 2019 2012 2013 2014 2015 2016 2017 2018 2019 Sanofi suspends production Merck announces shortages Sanofi discontinues all global Merck announces supply of BCG Connaught strain of BCG Tice strain production of BCG constraints o

  41. Slide 41: FDA approval probability of success increases upon BLA submission

    FDA approval probability of success for oncology products increases significantly upon BLA submission Oncology Products Reviewed by FDA 2006 - 2015 Phase Probability of Approval Products at end of Phase I 5% Products at end of Phase II 8% Products at end of Phase III 33% Products with BLA Submission

  42. Slide 42: Significant unmet need for innovative therapies to treat NMIBC

    Significant unmet need for innovative medical therapies to treat NMIBC Only 3 products have ever been approved by the FDA for NMIBC Product FDA Approval Additional Product Information Thiotepa 1959 Rarely used in current treatment regimens BCG* 1989 (Tice) Recommended first line treatment Surgery: R

  43. Slide 43: Radical cystectomy remains recommended option after BCG failure

    Radical cystectomy remains recommended treatment option after BCG failure 60-70% lifetime risk of cystectomy associated with NMIBC1 • Complex, long surgical procedure (10+ hours) • Significant rates of morbidity (30-60% within 90 days) and mortality (2-9% within 6 months)2 – 64% complication rate wi

  44. Slide 44: Vicinium: A single cGMP Manufacturing Process

    Vicinium: A single cGMP Manufacturing Process Vicinium cGMP manufacturing process producing a single fusion protein � Inexpensive � Reliable � Simple (linear) QA QA Purification Release Fill/Finish Release Bioreactor (Generates Drug (Generates Drug Market Substance) Product) Single cGMP process ADCs

  45. Slide 45: Vicinium Patent Life

    Vicinium Patent Life Pending Applications Dosing Strategies for Targeting EPCAM positive bladder cancer. If allowed, Stabilized Chimeric Immunoglobulins would expire in 2036 or later. (Oct 2021- Jan 2022) US: 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 M

Sesen Bio — Q1 2019 Earnings Presentation on 6ix